The GSK Board has declared a fourth interim dividend for 2023 of 16.00p per share (Q4 2022: 13.75p per share).
Other financial highlights include:
•Total 2023 sales £30.3 billion +5% and +14% ex COVID
•Vaccines sales +25%, +24% ex COVID. Shingrix £3.4 billion +17%, Arexvy £1.2 billion
•Specialty Medicines sales -8%, +15% ex COVID with HIV +13%; General Medicines sales +5%
•Total operating profit and Total continuing EPS for 2023 reflects strong growth, with lower charges for contingent consideration liabilities remeasurement
•Adjusted operating profit +12% (with further positive impact of +4% ex COVID) and Adjusted EPS +16% (with further positive impact of +6% ex COVID). This reflected strong sales ex COVID and higher royalty income, partly offset by increased investment in R&D and new product launches
